Based on these results, reducing TLR4/MyD88 pathway signaling in cardiomyocytes by reducing gut-derived LPS levels is one of the key mechanisms by which myricetin affects DCM. This evidence concerns the gene MYD88 and familial dilated cardiomyopathy.